kinthera bpc 157 BPC-157 + TB-500 — 10 mg BPC-157 Europe - RUO Research

The 10 mg dose achieved 21.4%, and even the 5 mg dose delivered 16.0%

Some protocols use two-week escalation intervals with higher starting doses

In this Review, we focus on advances in our understanding of inhibition of the HGF/c-MET pathway in patients with gastro-intestinal cancers, the prominent challenges facing the clinical translation and implementation of agents targeting HGF/c-MET, and discuss the various efforts, and associated obstacles to the discovery and validation of biomarkers that will enable patient stratification in this context

It is the protocol patients choose when they want to feel better and look better at the same time